Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$55.98 USD
-0.32 (-0.57%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $55.95 -0.03 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Brokerage Reports
Cytokinetics, Incorporated [CYTK]
Reports for Purchase
Showing records 1 - 20 ( 310 total )
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Full Speed Ahead at Cytokinetics Regardless of Any BD Plans; Target Adjusted to $90
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Full Case Is Made; Aficamten Should be HCM Leader
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
1Q24 Results; Prepping for Global Regulatory Submissions in 2H24 Following Full SEQUOIA-HCM on Monday
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Phase 1 Sneak Peek Reveals a Safe Profile for CK-586
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
FOREST-HCM Keeps Planting Strong Roots After One-Year Follow-Up
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
2023 Results; Prepping for First Global Commercial Launch; Aficamten Regulatory Submissions in 2H24; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Magnetic Resonance Data Unveil Aficamten?s Long- Term Benefits in Cardiac Remodeling; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Does Novartis Back Away on Street-Driven Valuation? Focus on Aficamten Potential; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Wait, There Was Still One More Big Gift Under the Tree; SEQUOIA Nails It; Target Upped to $94
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Critical Near-Term Data Catalysts In Our Universe Represent Thesis Definers
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for CYTK 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
3Q23 Results; Projecting Happy Holidays Built on Strong Roots; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Acquisition Makes Sense, But Cytokinetics Certainly Has Options
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Shaping a Specialty Cardiology Franchise; Aficamten Pivotal Readout by YE23; Target Upped to $58
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
SEQUOIA-HCM Gathers Diverse and Representative oHCM Population for Aficamten Evaluation
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
ACACIA-HCM Phase 3 Trial Embarks on its Journey as Enrollment Initiates
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
2Q23 Results; One Word: SEQUOIA; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Myosin Inhibitor vs. Beta Blocker; Development of Aficamten Expands with Phase 3 MAPLE-HCM Trial
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
REDWOOD-HCM Cohort 4 Brings Aficamten to the Top of the Tree; Phase 3 Initiation in nHCM in 2H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J